Introduction
The present chemotherapy of cancer uses agents that are usually toxic to normal cells. On the other hand, induction of cellular differentiation may supplement the use of cytotoxic drugs in several forms of neoplasia, like the successful use of all-transretinoic acid (ATRA) in the treatment of acute promyelocytic leukemia. The physiologically active form of vitamin D 3 , 1,25(OH) 2 D 3 , is a member of the secosteroid hormone family, which controls calcium homeostasis and bone metabolism. 1,25(OH) 2 D 3 can induce differentiation and inhibit the growth of a number of malignant cell types, including myeloid leukemia, breast, prostate, colon, skin, and brain. Several studies suggested that growth inhibition by 1,25(OH) 2 D 3 may be attributed to inhibition of the G 1 to S transition in the cell cycle, which probably is due at least in part to stimulation of expression of the cyclin-dependent kinase inhibitors (CDKIs), p21 waf1 and p27 kip1 as well as induction of programmed cell death. [1] [2] [3] [4] In a clinical study, oral administration of 1,25(OH) 2 D 3 to preleukemic patients was only partially effective 5 ; calcemic side effects prevented the administration of the dosage of the compound needed to achieve the concentration of 1,25(OH) 2 D 3 in vivo, which was known to be necessary from our in vitro studies. 5, 6 Therefore, synthesis of vitamin D 3 analogs with potent antiproliferative and differentiation activity against cancer cells with decreased risk of hypercalcemia has received considerable attention. [7] [8] [9] [10] [11] [12] [13] [14] Recently, PTEN/MMAC1/TEP1, a tyrosine phosphatase, was identified and mapped to chromosome 10q23.3. [15] [16] [17] PTEN gene mutations have been observed in a variety of human cancers including breast, prostate, brain, lymphoma, and leukemia. 15, [18] [19] [20] [21] [22] [23] Germline deletion of PTEN in the mouse resulted in early embryonic lethality, and heterozygous mice developed malignant neoplasms. 24, 25 These findings strongly suggested that PTEN is a candidate tumor suppressor.
In this study, a class of newly synthesized vitamin D 3 analogs having 2 identical side chains attached to carbon-20 was analyzed. We focused particularly on the most active analog, which has a deletion of C-19, 21-(3-methyl-3-hydroxy-butyl)-19-nor D 3 (Gemini-19-nor). This new vitamin D 3 analog was more potent than 1,25(OH) 2 D 3 in mediating growth inhibition, differentiation, apoptosis, G 1 /G 0 arrest of the cell cycle, and expression of p27 kip1 . Furthermore, we observed that this compound induced the expression of PTEN in myeloid leukemic cells as the cells underwent differentiation.
Materials and methods

Cells and compounds
The myeloid leukemia (HL-60), breast cancer (MCF-7), and prostate cancer (LNCaP) cell lines were obtained from American Type Culture Collection (Rockville, MD). The NB4 promyelocytic leukemia cell line was provided by Dr Lanotte (INSERM, Hospital Saint-Louis, Paris, France). HL-60, NB4, and LNCaP were cultured in RPMI 1640 with 10% fetal calf serum (FCS). MCF-7 cells were maintained in Dulbecco modified Eagle media with 10% FCS. All 4 cell lines were maintained in a 37°C incubator containing 5% CO 2 . After informed consent, mononuclear cells from normal bone marrow were collected by separation on Ficoll-Hypaque (Pharmacia, Piscataway, NJ) gradients at a density of 1.077, and washed in Iscove modified Dulbecco medium (IMDM) containing 10% FCS.
All vitamin D 3 analogs were synthesized by Milan R. Uskokovic (Hoffmann-La Roche, Nutley, NJ). The analogs are shown in Figure 1 . The vitamin D 3 compounds were dissolved in absolute ethanol at 10 Ϫ3 M as stock solution, which were stored at Ϫ20°C and protected from light. 12-O-Tetradecanoylphorbol 13-acetate (TPA) and ATRA were purchased from Sigma (St Louis, MO).
Soft agar colony assay
Cells were cultured in a 2-layer soft agar system for either 7 days (HL-60 and NB4) or 10 days (MCF-7 and LNCaP) as described previously. 26 Normal bone marrow cells were cultured for 14 days in methylcellulose medium M3234 (Stem Cell Technology, Vancouver, BC, Canada) containing 20 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF). MCF-7 and LNCaP cells were trypsinized, washed, counted, and plated into 24-well, flat-bottom plates with a total of 1 ϫ 10 3 cells/well in a volume of 400 L/well. The feeder layer was prepared with agar that had been equilibrated at 42°C. Prior to this step, vitamin D 3 compounds were pipetted into the wells. After incubation, the colonies were counted. All experiments were done at least 3 times using triplicate plates per experimental point.
Analysis of differentiation
Expression of cell surface antigens was determined by flow cytometry. HL-60 cells were cultured with either 1,25(OH) 2 D 3 or Gemini-19-nor (10 Ϫ8 and 10 Ϫ7 M) for 4 days. After twice washing with phosphate-buffered saline (PBS), cells were incubated for 30 minutes with fluorescein isothiocyanate (FITC)-conjugated murine antihuman CD11b or antihuman CD14 antibody (DAKO, Carpinteria, CA). Murine IgG1 antibody (DAKO) was used as negative control. Cells were analyzed by a FACScan (Becton Dickinson, Mountain View, CA). HL-60 cells were assessed for their ability to produce superoxide as measured by reduction of nitroblue tetrazolium (NBT), by morphology as detected on cytospin preparations stained with DiffQuick Stain Set (Baxter Healthcare, Miami, FL). All experiments were independently done at least 3 times. All data were statistically analyzed by Student t test.
Cell cycle analysis
Cell cycle analysis was performed on HL-60 cells incubated for 4 days with either 1,25(OH) 2 D 3 or Gemini-19-nor at either 10 Ϫ8 or 10 Ϫ7 M. The cells were fixed in chilled methanol overnight before staining with 50 g/mL propidium iodide (PI), 1 mg/mL RNase, and 0.1% NP40. Analysis was performed immediately after staining using a FACScan (Becton Dickinson) and CELLFit program (Becton Dickinson). All experiments were independently performed at least 3 times. All data were statistically analyzed by Student t test.
Apoptosis analysis
To study induction of apoptosis by vitamin D 3 analogs, annexin V assay (Annexin V-FITC Apoptosis Detection Kit; Pharmingen, San Diego, CA) was performed according to the manufacturer's instructions. Briefly, cells were harvested after exposure with either 1,25(OH) 2 D 3 or Gemini-19-nor (10 Ϫ8 and 10 Ϫ7 M), washed twice with PBS, incubated with FITCconjugated annexin V and PI for 15 minutes, and measured by FACScan (Becton Dickinson). All experiments were independently done at least 3 times. All data were statistically analyzed by Student t test.
Western blot analysis
Cells were washed twice in PBS, suspended in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.1% sodium dodecyl sulfate [SDS], 0.5% sodium deoxycholate, 1% NP40, 100 g/mL phenylmethylsulfonyl fluoride, 2 g/mL aprotinin, 1g/mL pepstatin, and 10 g/mL leupeptin), and placed on ice for 30 minutes. After centrifugation at 15 000g for 20 minutes at 4°C, the supernatant was collected. Protein concentrations were quantitated using the Bio-Rad assay (Bio-Rad Laboratories, Hercules, CA). Whole lysates (40 g) were resolved by 4% to 15% SDS-polyacrylamide gel, transferred to an immobilon polyvinylidene difuride membrane (Amersham, Arlington Heights, IL) and probed with anti-p27 kip1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), anti-PTEN antibody (Santa Cruz Biotechnology), and anti-GAPDH antibody (Research Diagnostics, Flanders, NJ). The blots were developed using the enhanced chemoluminescence (ECL) kit (Amersham). Band intensity was measured using a densitometer and fold increase in expression as compared to control, untreated cells was calculated.
Results
Effect of vitamin D 3 analogs on clonal proliferation
The myeloid leukemia (HL-60 and NB4), breast cancer (MCF-7), and prostate cancer (LNCaP) cells were cloned in soft agar in the Results derived from Figure 2 ; the concentration of vitamin D3 compound that induced 50% clonal inhibition (ED50). HL-60, human myeloblastic leukemia cells; NB4, human acute promyelocytic cells; MCF-7, estrogen-receptor positive breast cancer cells; LNCaP, androgen receptor-positive prostate cancer cells. 
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Induction of expression of PTEN
Recent studies showed that the tumor suppressor PTEN was mutated or otherwise dysregulated in several types of human tumors. It is involved in the normal regulation of cell growth, the cell cycle, and apoptosis. 29, 30 We evaluated the effect of vitamin D 3 compounds on protein expression of PTEN in HL-60 cells that have no mutation, deletion, or methylation of this gene. 22 The nontreated, control HL-60 cells had a very low level of expression of PTEN as determined by Western blot analysis ( Figures 8A,B) . Expression markedly increased by 16-fold in HL-60 cells at 4 days of culture with 10 Ϫ9 M Gemini-19-nor; under the same culture conditions, the 1,25(OH) 2 D 3 (10 Ϫ9 M) did not induce detectable levels of PTEN ( Figure 8A ). At 10 Ϫ7 M, Gemini-19-nor and 1,25(OH) 2 D 3 increased the expression of PTEN by about 32-fold and 14-fold, respectively. A time course study showed that Gemini-19-nor enhanced expression of PTEN by 6-fold at 0.5 days and about 36-fold at 3 days of exposure ( Figure 8B) .
We also examined if other inducers of differentiation of HL-60 cells could up-regulate expression of PTEN. The phorbol diester, TPA, induces macrophage-like differentiation 31 and ATRA induces granulocyte-like differentiation of HL-60 cells. Four days of culture with either TPA (10 Ϫ9 M) or ATRA (10 Ϫ7 M) induced PTEN expression in HL-60 cells ( Figure 8C ).
Discussion
A recent study revealed that a vitamin D 3 compound that has 2 side chains on C-20 (Gemini) was more active than 1,25(OH) 2 D 3 in its ability to inhibit clonal growth of malignant cells. 32 Therefore, we synthesized additional novel Gemini compounds and examined their biologic effects on cancer cells. In this study, we evaluated 4 compounds from the newly synthesized family of Gemini. The Gemini-19-nor, which has 2 side chains on C-20 and the removal of the C-19, was the most potent inhibitor of clonal proliferation of myeloid leukemia, breast, and prostate cancer cells. It was more active than 1,25(OH) 2 D 3 in these 3 types of cancers. In particular, the analog showed marked activity with the NB4 acute promyelocyte leukemia cells and was 40 625-fold more potent than 1,25(OH) 2 34 When compared with these 19-nor analogs, Gemini-19-nor was about 100-fold more potent than 1,25S(OH) 2 -16,23-diene-26-F 3 -19-nor-D 3 when studied with NB4 cells, whereas it had either comparable or weaker activity than LH and 1,25S(OH) 2 -16,23-diene-26-F 3 -19-nor-D 3 with HL-60, MCF-7, and LNCaP cells. Therefore, even though study conditions were not completely identical, these data suggest that in some types of leukemia, Gemini-19-nor may be a more potent inhibitor of proliferation than 1,25S(OH) 2 -16,23-diene-26-F 3 -19-nor-D 3 , which was the most active vitamin D 3 analog against myeloid leukemia cells in previous studies. In contrast to the effect on tumor cell lines, Gemini-19-nor (10 Ϫ10 M to 10 Ϫ8 M) did not inhibit the clonal growth of normal human bone marrow committed myeloid stem cells (CFU-GM).
Exposure of HL-60 myeloid leukemia cells to either 1,25(OH) 2 D 3 or Gemini-19-nor induced the expression of the cell surface markers, CD11b and CD14. Gemini-19-nor (10 Ϫ8 M) induced expression of CD11b and CD14 in about 90% and 75% of cells, whereas the same concentration of 1,25(OH) 2 D 3 induced expression on only 50% and 30% of cells, respectively. Similarly, Gemini-19-nor (10 Ϫ8 M) induced 70% of HL-60 cells to become NBT ϩ , compared to only 30% for the same concentration of 1,25(OH) 2 D 3 . Therefore, these results suggested that Gemini-19-nor was more potent than 1,25(OH) 2 D 3 as an inducer of myeloid differentiation.
Gemini-19-nor also mediated apoptosis. Previously, we reported that vitamin D 3 analogs in concert with a RXR ligand induced apoptosis of myeloid leukemia cells and caused levels of expression of Bcl-2 to decrease suggesting an association between the 2 events. 3, 4, 35 However, other experiments found that a vitamin D 3 analog could induce apoptosis of an HL-60 variant without a reduction of cellular levels of Bcl-2. 4 Another group reported that vitamin D 3 compounds induced apoptosis via a novel caspase-and p53-independent pathway, and apoptosis was inhibited by forced expression of Bcl-2. 36 These findings suggested that vitamin D 3 might use several pathways to induce apoptosis.
Previous studies showed that vitamin D 3 analogs caused accumulation at the G 1 /G 0 phase of the cell cycle, and this block may be mediated by p21 waf1 and p27 kip1 CDKIs. 2, 26, 37 Gemini-19-nor D 3 also produced G 1 -to S-phase block of the cell cycle and induced p27 kip1 expression. These results support the hypothesis that CDKIs mediated at least in part the antiproliferative affects of the vitamin D 3 compounds by induction of a G 1 /G 0 accumulation. A block in the G 2 /M checkpoint has also been previously observed in HL-60 cells treated with 1,25(OH) 2 D 3 , 38 and Gemini-19-nor was able to more potently induce a G 2 /M block compared to 1,25(OH) 2 D 3 . This effect has been attributed to a decrease in levels of p34(cdc), 39 a protein kinase which associates with B-type cyclins and controls transition through G 2 /M. Therefore Gemini-19-nor may be able to decrease levels of this protein to a greater extent than 1,25(OH) 2 D 3 . Recent studies indicated that the candidate tumor suppressor, PTEN, could block the phosphatidylinositol 3Ј-kinase (PI3K)/Akt signaling pathway, resulting in cell death or inhibition of growth or both. 29, 30 Activated Akt mediates cell survival by inhibition of mitochondrial release of cytochrome c, inactivation of Forkhead transcription factors (FKHR), and phosphorylation of BAD and caspase-9. 40 The overexpression of exogenous PTEN induced apoptosis of malignant cells. [41] [42] [43] [44] [45] Moreover, a genetic link between the Fas proapoptotic pathway and PTEN was suggested, because Fas-mediated apoptosis was impaired in the germline heterozygous PTEN ϩ/Ϫ murine model. 46 In addition, PTEN induced G 1 cell cycle arrest and this was associated with an increased expression of p27 kip1 . 45, [47] [48] [49] [50] [51] [52] [53] In the present study, Western blotting analysis demonstrated that PTEN expression was up-regulated by vitamin D 3 compounds in HL-60 cells, and it paralleled the induction of apoptosis, expression of p27 kip1 and G 1 cell cycle arrest. These findings suggest that PTEN might enhance apoptosis and G 1 cell cycle arrest in transformed cells exposed to a vitamin D 3 analog, and it might help explain the multiple pathways of apoptosis mediated by vitamin D 3 compounds.
Several studies indicated that PTEN induced cell differentiation in glioma cells. 54, 55 Therefore, we analyzed inducers of myeloid differentiation other than vitamin D 3 . We choose TPA, a stimulator of the protein kinase C pathway that induces macrophage-like differentiation, and ATRA, which binds the nuclear hormone receptor, retinoic acid receptor and induces granulocytic differentiation. As shown in Figure 6C , TPA and ATRA significantly induced PTEN expression. These observations suggest that PTEN expression is associated with monocytic and granulocytic differentiation. We do not know if this marked increase in PTEN expression is the cause or the effect of terminal differentiation of HL-60 cells. Further studies are required to define the role PTEN plays in this process of myeloid differentiation.
Taken together, the new vitamin D 3 analog Gemini-19-nor D 3 strongly inhibited growth of transformed cells, and produced myeloid differentiation, apoptosis, and G 1 /G 0 arrest associated with elevated levels of p27 kip1 . Moreover, the vitamin D 3 analog induced expression of PTEN. These observations suggest that the anticancer effects of vitamin D 3 might be regulated in part via PTEN. This analog may provide an adjuvant therapy for myeloid leukemia, especially acute promyelocytic leukemia, and may be effective in other types of cancers. 
